Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Calero, Raul ^a,b   Morchon, Esther ^a   Johnsen, John Inge ^b   Serrano, Rosario ^a,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN MYCN; PROTEIN TYROSINE KINASE; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; INDOLE DERIVATIVE; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCN GENE; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; ANIMAL; CELL CYCLE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84899725519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095628     Document Type: Article

References (40)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120. (Pubitemid 46935947)
2. Johnsen JI, Kogner P, Albihn A, Henriksson MA (2009) Embryonal neural tumours and cell death. Apoptosis 14: 424-438.
3. Meitar D, Crawford SE, Rademaker AW, Cohn SL (1996) Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. JClinOncol 14: 405-414. (Pubitemid 26051001)
4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. nature 411: 355-365.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912-1934. (Pubitemid 35425239)
6. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapyinduced apoptosis via phosphatidylinositol 39-kinase pathway. Cancer Res 62: 6756-6763. (Pubitemid 35364148)
7. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462-6466. (Pubitemid 35364107)
8. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, et al. (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65: 9868-9875. (Pubitemid 41541466)
9. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, et al. (2008) Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. ClinCancer Res 14: 6531-6537.
10. Weber A, Huesken C, Bergmann E, Kiess W, Christiansen NM, et al. (2003) Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. ClinCancer Res 9: 5683-5692. (Pubitemid 37499491)
11. Kim B, van Golen CM, Feldman EL (2004) Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene 23: 130-141. (Pubitemid 38142247)
12. Schwab TS, Madison BB, Grauman AR, Feldman EL (2005) Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis 10: 831-840. (Pubitemid 41187081)
13. Misawa A, Hosoi H, Arimoto A, Shikata T, Akioka S, et al. (2000) N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 60: 64-69. (Pubitemid 30058732)
14. Richardson DS, Lai AZ, Mulligan LM (2006) RET ligand-induced internalization and its consequences for downstream signaling. Oncogene 25: 3206-3211. (Pubitemid 43881561)
15. Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, et al. (2002) Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. JPediatrSurg 37: 582-587. (Pubitemid 34293096)
16. Opel D, Poremba C, Simon T, Debatin KM, Fulda S (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745. (Pubitemid 46192214)
17. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67-78.
18. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, et al. (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922. (Pubitemid 351620441)
19. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. (2006) Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146. (Pubitemid 44299181)
20. Grimmer MR, Weiss WA (2006) Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 18: 634-638. (Pubitemid 44747156)
21. Galderisi U, Di Bernardo G, Cipollaro M, Jori FP, Piegari E, et al. (1999) Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J Cell Biochem 74: 313-322. (Pubitemid 29344883)
22. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, et al. (2002) In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. IntJCancer 102: 351-354. (Pubitemid 35265875)
23. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, et al. (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19: 2054-2065. (Pubitemid 41247962)
24. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, et al. (2008) N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 27: 3999-4007. (Pubitemid 351913633)
25. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
26. Ocana A, Serrano R, Calero R, Pandiella A (2009) Novel tyrosine kinase inhibitors in the treatment of cancer. CurrDrug Targets 10: 575-576.
27. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ (2002) Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16: 77-85. (Pubitemid 34624816)
28. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. JClinOncol 24: 25-35. (Pubitemid 46630490)
29. Segerstrom L, Baryawno N, Sveinbjornsson B, Wickstrom M, Elfman L, et al. (2011) Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. IntJCancer 129: 2958-2965.
30. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
31. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290. (Pubitemid 47574858)
32. Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, et al. (2011) Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. MolCancer Ther 10: 697-707.
33. Rossler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, et al. (2009) EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res 29: 1327-1333.
34. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, et al. (2008) Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. MolCancer Ther 7: 418-424. (Pubitemid 351302535)
35. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, et al. (2010) Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene.
36. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, et al. (2009) In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11: 426-435.
37. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, et al. (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. NeuroOncol 9: 412-423.
38. Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, et al. (2006) Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 97: 945-951. (Pubitemid 44151278)
39. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, et al. (2012) Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 4: 115ra113.
40. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, et al. (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res 70: 10351-10361.